Ultragenyx Pharmaceutical Inc.
RARE
Market Cap$3.32B
Close$
$55.30
43.1% upside
Current Fair Value
43.1% upsideUndervalued by 43.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.32 Billion |
|---|---|
| Enterprise Value | $2.90 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-7.96 |
| Beta | 1.19 |
| Outstanding Shares | 83,133,341 |
| Avg 30 Day Volume | 741,865 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.41 |
|---|---|
| PEG | -132.12 |
| Price to Sales | 7.73 |
| Price to Book Ratio | 38.65 |
| Enterprise Value to Revenue | 6.56 |
| Enterprise Value to EBIT | -5 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis